Literature DB >> 28740654

A novel therapeutic approach for esophageal squamous cell carcinoma: suppressor of cytokine signaling-1 gene therapy.

Chang-Han Chen1,2,3, Shau-Hsuan Li4.   

Abstract

Entities:  

Year:  2017        PMID： 28740654      PMCID： PMC5506160          DOI： 10.21037/jtd.2017.05.57

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

2.  Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer.

Authors:  Junfen Ma; Jimin Zhao; Jing Lu; Yanan Jiang; Hongyan Yang; Pei Li; Mingyao Zhao; Kangdong Liu; Ziming Dong
Journal:  Int J Mol Med       Date:  2012-09-19       Impact factor: 4.101

Review 3.  Three-field lymph node dissection in treating the esophageal cancer.

Authors:  Qi-Xin Shang; Long-Qi Chen; Wei-Peng Hu; Han-Yu Deng; Yong Yuan; Jie Cai
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Authors:  Yaohe Wang; Stephen Thorne; Joseph Hannock; Jennelle Francis; Tina Au; Tony Reid; Nick Lemoine; David Kirn; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

Review 5.  Role of SOCS1 in tumor progression and therapeutic application.

Authors:  Jing Zhang; Hui Li; Jin-Pu Yu; Shizhen Emily Wang; Xiu-Bao Ren
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

6.  Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity.

Authors:  Lei Shen; Kevin Evel-Kabler; Randy Strube; Si-Yi Chen
Journal:  Nat Biotechnol       Date:  2004-11-21       Impact factor: 54.908

7.  Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.

Authors:  Kazuki Shimada; Satoshi Serada; Minoru Fujimoto; Shintaro Nomura; Rie Nakatsuka; Emi Harada; Kota Iwahori; Isao Tachibana; Tsuyoshi Takahashi; Atsushi Kumanogoh; Tadamitsu Kishimoto; Tetsuji Naka
Journal:  Cancer Sci       Date:  2013-09-19       Impact factor: 6.716

8.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

Review 9.  Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment.

Authors:  Mengmeng Jiang; Wen-Wen Zhang; Pengpeng Liu; Wenwen Yu; Ting Liu; Jinpu Yu
Journal:  Front Immunol       Date:  2017-02-08       Impact factor: 7.561

10.  Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation.

Authors:  Shau-Hsuan Li; Hung-I Lu; Alice Y W Chang; Wan-Ting Huang; Wei-Che Lin; Ching-Chang Lee; Wan-Yu Tien; Ya-Chun Lan; Hsin-Ting Tsai; Chang-Han Chen
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.